Vitamin D as a Cytokine and Hematopoetic Factor

Reviews in Endocrine and Metabolic Disorders

Volumn 2, Issue 2, 2001, Pages 217-227

  Hewison, Martin ^b   Gacad, Mercedes A ^a   Lemire, Jacques ^c   Adams, John S ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

25 dihydroxyvitamin D; Analogs cytokine; Hypercalcemia; Immunoinhibitory; Myeloid differentiation; Vitamin D

Indexed keywords

CYTOKINE; VITAMIN D;

ANIMAL; BIOSYNTHESIS; CELLULAR IMMUNITY; HEMATOPOIESIS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; CYTOKINES; HEMATOPOIESIS; HUMANS; IMMUNITY, CELLULAR; VITAMIN D;

EID: 0035317860     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010015013211     Document Type: Article

References (94)

1. 3: a novel immunoregulatory hormone. Science 1984:1438-1441.
2. 3. Proc Natl Acad Sci USA 1981;78:4990-4999.
3. 3 by cultured alveolar macrophages in sarcoidosis. J Clin Invest 1983;72:1856-1860.
4. 3 produced by cultured alveolar macrophages in sarcoidosis. J Clin Endocrinol Metab 1985;60:960-966.
5. Fu GK, Lin D, Zhang MYH, Bikle DD, Shackleton CH, Miller WL, Portale AA. Cloning of human 25-hydroxyvitamin D-1alpha-hydroxylase and mutations causing vitamin D-dependent rickets type I. Mol Endocrinol 1997;11:1961-1970.
6. Fu GK, Portale AA, Miller WL. Complete structure of the human gene for the vitamin D 1alpha-hydroxylase, P450c 1alpha. DNA Cell Biol 1997;12:1499-1507.
7. 3 1alpha-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestations. J Clin Endocrinol Metab 1999;84:4111-4117.
8. Smith SJ, Rucka AK, Berry JL, Davies M, Mylchreest S, Paterson CR, Heath DA, Tassabehji M, Read AP, Mee AP, Mawer EB. Novel mutations in the 1α-hydroxylase (P450c1) gene in three families with pseudovitamin D-deficiency rickets resulting in loss of functional enzyme activity in blood-derived macrophages. J Bone Miner Res 1999;14:730-739.
9. Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL. Hypercalcemia in an anephric patient with sarcoidosis. N Engl J Med 1981;305:440-443.
10. 3 sterols by cultured macrophages from patients with sarcoidosis. J Exp Med 1985;161:755-765.
11. Bell NH. Renal and nonrenal 25-hydroxyvitamin D-1alpha-hydroxylases and their clinical significance. J Bone Miner Res 1998;13:350-353.
12. Okuda KI, Usui E, Ohyama Y. Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. J Lipid Res 1995;36:1641-1652.
13. Adams JS, Ren S-Y, Arbelle JE, Clemens TL, Shany S. A role for nitric oxide in the regulated expression of the 25-hydroxyvitamin D-1-hydroxylation reaction in the chick myelomonocytic cell line HD-11. Endocrinology 1994;134:499-502.
14. Adams JS, Ren S-Y. Autoregulation of 1,25-dihydroxyvitamin D synthesis in macrophage mitochondria by nitric oxide. Endocrinology 1996;137:4514-4517.
15. Adams JS, Modlin RL, Diz MM, Barnes PE Potentiation of the macrophage 25-hydroxylation reaction by human tuberculous pleural effusion fluid. J Clin Endocrinol Metab 1989;69:457-460.
16. 3 receptors in human leukocytes. Science 1983;221:1181-1182.
17. 3 in human peripheral blood mononuclear cells. J Clin Endocrinol Metab 1983;57:1308-1310.
18. Rigby W. The immunobiology of vitamin D. Immunol Today 1988;9:54-58.
19. Hewison M. Vitamin D and the immune system. J Endocrinol 1992;132:173-175.
20. Fagan DL, Prehn JL, Jordan SC, Adams JS. The human myelomonocytic cell line U937 as a model for studying alterations in monokine gene expression by 1,25-dihydroxyvitamin D. Mol Endocrinol 1991;5:179-186.
21. 3. Proc Natl Acad Sci USA 1983;80:5907-5910.
22. Lemire JM, Adams JS, Kermani-Arab V, Bakke AC, Sakai R, Jordan SC. 1,25-Dihydroxyvitamin D suppresses human T helper-inducer lymphocyte activity in vitro. J Immunol 1985;134:219-224.
23. 3 on human lymphocytes and monocyte/ macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol 1986;98:311-322.
24. Ucla C, Roux-Lombard P, Dayer J-M, Mach B. IFN-gamma drastically modifies the regulation of IL-1 genes by endotoxin in U937 cells. J Clin Invest 1990;85:185-191.
25. 3. J Immunol 1986;136:2181-2186.
26. 3, gamma-interferon, and control of proliferation of myobacterium tuberculosis by human monocytes. Immunology 1986;57:159-163.
27. Jordan SC, Lemire JM, Kieffler PK, Sakai R, Adams JS. Immunoregulatory and prodifferentiating effect of 1,25-dihydroxyvitamin D. In: Nutrient Modulation of the Immune Response. New York: Marcel Dekker, 1992;3-29.
28. Manolagas SC, Provvedini DM, Murray EJ, Tsoukas CD, Deftos LJ. The antiproliferative effect of calcitriol on human peripheral blood mononuclear cells. J Clin Endocrinol Metab 1986;63:394-400.
29. 3 on human T lymphocyte activation and proliferation. J Immunol 1985;135:2279-2286.
30. 3. Immunology 1986;59:479-484.
31. Lemire JM, Adams JS, Sakai R, Jordan SC. 1,25-Dihydroxyvitamin D suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 1984;74:857-861.
32. Rigby WFC, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-(OH)2D3. J Clin Invest 1987;79:1659-1664.
33. Lemire JM, Adams JS. 1,25-Dihydroxyvitamin D inhibits delayed-type hypersensitivity mediated by T-cell clones inducing experimental autoimmune encephalomyelitis. J Bone Miner Res 1992;7:171-178.
34. 3: preferential inhibition of Th1 functions. J Nutr 1995;125:1704S-1708S.
35. 3. J Steroid Biochem Mol Biol 1995;53:599-602.
36. Barnes PF, Modlin RL, Bikle DD, Adams JS. Transpleural gradient of 1,25-dihydroxyvitamin D in tuberculous pleuritis. J Clin Invest 1989;83:1527-1532.
37. 3 metabolites and tumor necrosis factor in the pathogenesis of tuberculosis. Immunology 1987;62:229-234.
38. Rook GAW The role of vitamin D in tuberculosis. Am Rev Respir Dis 1988;138:768-770.
39. Mawer EB, Hayes ME, Still PE, Davies M, Lumb GA, Palit J, Holt PJL. Evidence for nonrenal synthesis of 1,25-dihydroxyvitamin D in patients with inflammatory arthritis. J Bone Miner Res 1988;6:733-739.
40. Hayes ME, Bayley D, Still P, Palit J, Denton J, Freemont AJ, Cooper RG, Mawer EB. Differential metabolism of 25-hydroxyvitamin D3 by cultured synovial fluid macrophages and fibroblast-like cells from patients with arthritis. Ann Rheum Dis 1992;51:220-226.
41. 3 in macrophages from CAPD patients. FEBS 1987;220:307-310.
42. Shany S, Rapoport J, Zuili I, Gavriel A, Lavi N, Chaimovitz C. Metabolism of 25-OH-vitamin D3 by peritoneal macrophages from CAPD patients. Kid Int 1991;39:1005-1011.
43. Bunce CM, Brown G, Hewison M. Vitamin D and hematopoiesis. Trends in Endocrinology and Metabolism 1997;8:245-251.
44. Bouillon R, Okamura WH, Norman AW. Structure-function-relationships in the vitamin D endocrine system. Endocr Rev 1995;16:200-257.
45. Bouillon R, Garmyn M, Verstuyf A, Segaert S, Casteels K, Mathieu C. Paracrine role for calcitriol in the immune-system and skin creates new therapeutic possibilities for vitamin D analogs. European J Endocrinol 1995;133:7-16.
46. Munker R, Norman AW, Koeffler HP. Vitamin D compounds: effect on clonal proliferation and differentiation of human myeloid cells. J Clin Invest 1986;78:424-430.
47. Grande A, Manfredini R, Pizzanelli M, Tagliafico E, Balestri R, Trevisan F, Barbieri D, Franceschi C, Battini R, Ferrari S, Ferrari S. Presence of a functional vitamin D receptor does not correlate with vitamin D3 phenotypic effects in myeloid differentiation. Cell Death Differentiation 1997;4:497-505.
48. 3. Proc Natl Acad Sci USA 1981;78:4990-4994.
49. 3 and its fluorinated analogs. Cancer Res 1984;44:5624-5628.
50. 3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol 1984;98:391-398.
51. 3 induces maturation of the human monocyte cell line U937, and, in association with a factor from human T-lymphocytes, augments production of the monokine, mononuclear cell factor. J Clin Invest 1984;73:731-739.
52. 3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal bone marrow cells. Leukocyte Res 1983;7:51-54.
53. 3 receptor RNA expression in hematopoietic cells. Blood 1991;77:1238-1247.
54. Hewison M, Barker S, Brennan A, Nathan J, Katz DR, O'Riordan JLH. Autocrine regulation of 1,25-dihydroxycholecalciferol metabolism in myelomonocytic cells. Immunology 1989;68:247-252.
55. 3 in induction of myeloid differentiation of human leukemic cell lines. J Leukoc Biol 1992;51:237-243.
56. James SY, Williams MA, Kelsey SM, Newland AC, Colston KW. Interaction of vitamin D derivatives and granulocyte-macrophage colony-stimulating factor in leukaemic cell differentiation. Leukemia 1997;11:1017-1025.
57. 3 and retinoic acid (all trans or 9-cis). J Steroid Biochem Molecular Biol 1995;53:431-441.
58. Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, Naar AM, ErdjumentBromage H, Tempst P, Freedman LP. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999;398:824-828.
59. Muller R, Curran T, Muller D, Guilbert L. Induction of c-fos during myelomonocytic differentiation and macrophage proliferation. Nature 1985;314:546-548.
60. Karmali R, Bhalla A, Farrow SM, Lydyard P, O'Riordan JLH. 1,25-dihydroxycholecalciferol regulates oncogene expression in U937 cells. J Mol Endocrinology 1989;3:43-50.
61. 3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 1999;93:2721-2729.
62. Lill MC, Fuller JF, Herzig R, Crooks GM, Gasson JC. The role of the homeobox gene, Hox B7, in human myelomonocytic differentiation. Blood 1995;85:692-697.
63. 3 induction in myeloid leukemic cells. Mol Cell Biol 1998;18:1911-1918.
64. Ogata E. The potential use of vitamin D analogs in the treatment of cancer. Calc Tissue Int 1997;60:130-133.
65. 3 prolong survival time of mice innoculated with myeloid leukaemia cells. Cell Biol 1983;80:201-204.
66. 3. J Clin Invest 1998;101:252-262.
67. 3 inhibits the production of IL-12 by human monocytes and B cells. FASEB 1993;8:A745.
68. 3 suppresses human helper/ inductor lymphocyte activity in vitro. J Immunol 1985;34:3032-3035.
69. 3. J Clin Invest 1987;79:1659-1664.
70. 3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1987;84:3385-3389.
71. 3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 1985;74:657-661.
72. 3 mediated inhibition of B cell function in vitro. Immunopharmacology 1991;21:121-128.
73. 3 selectively interferes with cellular mechanisms of cytotoxicity. Kidney Intl 1990;37:420.
74. 3. Cell Immunol 1989;118:328-336.
75. 3. Scand J Immunol 1989;30:199-208.
76. 3 enhances generation of non-specific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR. Cell Immunol 1992;140:400-409.
77. 3 downregulation of HLA-DR on human peripheral blood monocytes. Immunology 1992;75:349-354.
78. 3 exerts opposing effects to IL4 on MHC class II antigen expression, accessory activity and phagocytosis on human monocytes. Scand J Immunol 1993;38:535-540.
79. 3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-1107.
80. 3 reversibly blocks the progression of relapsing encephalomyelitis. Proc Natl Acad Sci USA 1996;93:7861-7864.
81. 3 in immunosuppression: Lessons from autoimmunity and transplantation In: Feldman D, Glorieux F, Pike JW, eds, Vitamin D. San Diego: Academic Press, 1997;1167-1181.
82. 3 prevents insulitis in NOD mice. Diabetes 1992;41:1491-1495.
83. 3, KH1060. Endocrinology 1995;136:866-872.
84. 3. Diabetologia 1994;37:552-558.
85. 3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. Clin Exp Immunol 1998;112:181-187.
86. 3 restores defect. Diabetes 1998;47:1033-1037.
87. 3 in combination with a short induction course of cyclosporin A. Endocrinology 1998;139:95-102.
88. 3 attenuates the expression of experimental murine lupus of MRL/1 mice. Autoimmunity 1992;12:143-148.
89. 16-cholecalciferol prolongs the survival of murine cardiac allografts. Transplantation 1992;54:762-763.
90. Veyron P, Pamphile R, Binderup L, Touraine JL. Two novel vitamin D analogs, KH 1060 and CB 966, prolong skin allograft survival in mice. Transpl Immunol 1993;1:72-76.
91. Johnsson C, Tufveson G. MC 1288. A vitamin D analog with immunosuppressive effects on heart and small bowel grafts. Transplant Int 1994;7:392-397.
92. 3) for the treatment of psoriasis. Brit J Derm 1996;134:1070-1078.
93. 3: Evaluation of skin involvement using non-invasive techniques. Acta Derm Venereol 1993;73:449-451.
94. Santana-Sahagun JE, Lemire J, Albani S, Eichenfield L, Weisman MH. Safety and tolerability of calcitriol therapy as a disease-modifying agent in systemic sclerosis: an open pilot study. American Society of Rheumatology Meeting, Boston, November, 1999.